Lucida Medical, Koelis, Sectra and Hampshire Hospitals NHS Foundation Trust complete first prostate fusion biopsy using integrated diagnostic pathway
Figure – Koelis software interface showing imported 3D prostate and lesion MRI contours from Lucida Medical
27 November 2025 – Cambridge, United Kingdom
Lucida Medical is thrilled to announce the successful completion of its first prostate fusion biopsy procedure at its pilot site Hampshire Hospitals NHS Foundation Trust (HHFT).
The procedure was performed using Lucida Medical’s Prostate Intelligence (Pi™), AI solution for prostate cancer, seamlessly deployed through Sectra’s Amplifier Service, and combined with the Koelis Trinity®, a leading MRI/Ultrasound fusion guidance system using proprietary Organ Based Tracking® technology.
This marks a key milestone in a strong collaborative effort to make the prostate cancer diagnostic pathway more efficient and improve patient outcomes.
The procedure combined advanced MRI analysis powered by Lucida Medical’s AI solution, Prostate Intelligence (Pi™), with ultrasound fusion-guided biopsy using the Koelis Trinity®. Sectra’s enterprise imaging platform enabled full interoperability across systems, allowing clinical teams to access imaging and reports at every stage of the diagnostic pathway. HHFT led the clinical implementation, bringing together radiology and urology teams to assess scans, plan the biopsy and perform the intervention.
This collaboration shows how clinical expertise and integrated technologies can drive more accurate, efficient, and timely decision-making across the prostate cancer pathway.
“We are delighted to have integrated Lucida Medical’s Prostate Intelligence (Pi™) AI solution for prostate cancer into our diagnostic pathway. We believe it will provide us with the opportunity to streamline our service reducing the time our patients spend on the journey from referral to diagnosis. We have been working with Lucida for a number of years now so it is particularly rewarding to see our efforts realised”, said Professor Richard Hindley, Consultant Urologist at HHFT.
Aarti Shah, Consultant Radiologist at HHFT, added: “This is the first time that AI has been used at the point of image acquisition, biopsy planning and contouring lesions for biopsy. We are using our experience as a pilot in our region and we hope to analyse our data at a patient and lesion level to see how Pi™ performs in this real-world deployment.”
Dr. Antoine Leroy, founder & CEO Koelis, commented: “Koelis is proud to collaborate on this first prostate fusion biopsy using integrated diagnostic pathway. The collaboration has the potential to streamline the workflow between radiology and urology, integrated with Koelis’ precise 3D ultrasound guidance, to enable faster and more confident decisions for every patient. We appreciate Lucida Medical’s leadership on this initiative in the UK.”
Dr. Antony Rix, CEO & Co-founder of Lucida Medical, stated: “This is an important step in strengthening the prostate cancer pathway. By using AI to support biopsy decisions, we’re helping clinicians deliver more consistent care from diagnosis through to intervention. We’re grateful to Hampshire Hospitals, Koelis and Sectra for making this possible.”